NeuroMab™ Anti-CXCR4 BBB Shuttle Antibody(NRZP-1022-ZP3571)

Figure 1 depicts a Biacore sensogram showing the binding affinity of CD33 antibody to purified CD33-his tagged protein.

Figure 2 depicts binding curves of CD33 antibodies 2F5 and 6C7 binding to CD33 on primary human dendritic cells.

Figure 3 depicts results showing that anti-CD33 antibodies lead to increased phagocytosis of E. coli by primary human macrophages.

Figure 4 depicts results showing a dose-dependent decrease in cell surface levels of CD33 on human primary monocytes treated with anti-CD33 antibodies 2E12, 6A3 and 6C7.

Figure 5 depicts results showing dose-dependent reduction in cell surface levels of CD33 on human primary dendritic cells treated with anti-CD33 antibodies 2E12, 6A3 and 6C7.

Figure 6 depicts the reduction of CD33 cell surface levels on human primary dendritic cells obtained from patient donor 258.

Figure 7 depicts the reduction of cell surface levels of CD33 on human primary dendritic cells obtained from patient donor 259.

Figure 8 depicts the percent change (% Delta) in cell surface reduction (downregulation) between cells from donors 258 and 259 treated with anti-CD33 antibody

Figure 9 depicts 12-point titration curves showing half maximal concentrations (EC50) of CD33 antibodies 2F5, 6C7, gemtuzumab and lintuzumab for reducing cell surface expression of CD33.

Figure 10 depicts 12-point titration curves showing the half maximal concentration (EC50) of CD33 antibodies 2F5, 6C7 and gemtuzumab for reducing cell surface expression of CD11c.

Figure 11 depicts cell surface levels of CD33 in human primary monocytes after treatment with CD33 antibody at different antibody concentrations.

Figure 12 depicts the cell surface levels of CD14 in human primary monocytes after treatment with CD33 antibody at different antibody concentrations.